发布求助
文献互助 智能选刊 最新文献

Section 7: Post Congress additions最新文献

筛选
英文 中文
2SPD-003 Telepharmacy in onco-haematologic patients: a 7-month experience 远程药房在肿瘤血液病患者:7个月的经验
Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.376
S. Barbadillo, V. Martínez Callejo, M. Ochagavía Sufrategui, A. García-Avello Fernández-Cueto, MV Villacañas Palomares, VS Carmen Maria, M. Martín López, M. Valero Domínguez
{"title":"2SPD-003 Telepharmacy in onco-haematologic patients: a 7-month experience","authors":"S. Barbadillo, V. Martínez Callejo, M. Ochagavía Sufrategui, A. García-Avello Fernández-Cueto, MV Villacañas Palomares, VS Carmen Maria, M. Martín López, M. Valero Domínguez","doi":"10.1136/ejhpharm-2022-eahp.376","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.376","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116040462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2SPD-012 Immunotherapy in patients with non-small cell lung cancer: effectiveness and safety in real life 非小细胞肺癌患者的免疫治疗:现实生活中的有效性和安全性
Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.377
R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo
{"title":"2SPD-012 Immunotherapy in patients with non-small cell lung cancer: effectiveness and safety in real life","authors":"R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo","doi":"10.1136/ejhpharm-2022-eahp.377","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.377","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131214907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
4CPS-257 Effectiveness and safety of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis 尼达尼布和吡非尼酮治疗特发性肺纤维化的有效性和安全性
Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.413
J. Pedreira Bouzas, EM García Rebolledo, C. Puivecino Moreno, M. García Gil
{"title":"4CPS-257 Effectiveness and safety of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis","authors":"J. Pedreira Bouzas, EM García Rebolledo, C. Puivecino Moreno, M. García Gil","doi":"10.1136/ejhpharm-2022-eahp.413","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.413","url":null,"abstract":"Background and importance Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a poor prognosis. Nintedanib and pirfenidone are the only drugs indicated for this path-ology. In pivotal clinical trials these drugs reduced the decline in forced vital capacity (FVC), which is consistent with a slowing of disease progression. and objectives Evaluation of the effectiveness and safety of nintedanib and pirfenidone in IPF in a second-level hospital.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"119 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131419359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
4CPS-215 Persistence and therapeutic adherence to first-generation Janus kinase inhibitors in rheumatoid arthritis patients 第一代Janus激酶抑制剂在类风湿关节炎患者中的持续性和治疗依从性
Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.405
C. Martinez-Molina, N. Pages, P. Riera, A. Riera, H. Codes, C. Díaz-Torné, H. Corominas, J. Ruiz-Ramos, M. Masip
{"title":"4CPS-215 Persistence and therapeutic adherence to first-generation Janus kinase inhibitors in rheumatoid arthritis patients","authors":"C. Martinez-Molina, N. Pages, P. Riera, A. Riera, H. Codes, C. Díaz-Torné, H. Corominas, J. Ruiz-Ramos, M. Masip","doi":"10.1136/ejhpharm-2022-eahp.405","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.405","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130084291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
4CPS-140 Antimicrobial stewardship programme in oncology patients through a multidisciplinary team 4CPS-140抗菌药物管理计划在肿瘤患者通过多学科团队
Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.398
A. Aguado Paredes, M. Romero González, J. Cordero Ramos, M. Beltrán García
{"title":"4CPS-140 Antimicrobial stewardship programme in oncology patients through a multidisciplinary team","authors":"A. Aguado Paredes, M. Romero González, J. Cordero Ramos, M. Beltrán García","doi":"10.1136/ejhpharm-2022-eahp.398","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.398","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133128442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
4CPS-029 Pembrolizumab, nivolumab and atezolizumab: incremental cost-effectiveness ratio Pembrolizumab, nivolumab和atezolizumab:增量成本-效果比
Section 7: Post Congress additions Pub Date : 2022-03-01 DOI: 10.1136/ejhpharm-2022-eahp.383
R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo
{"title":"4CPS-029 Pembrolizumab, nivolumab and atezolizumab: incremental cost-effectiveness ratio","authors":"R. Tamayo Bermejo, JC del Río Valencia, B. Mora Rodríguez, I. Muñoz Castillo","doi":"10.1136/ejhpharm-2022-eahp.383","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.383","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"301 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124297759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信